In rats with colocutaneous fistula, BPC‑157 given parenterally or perorally accelerated healing of the colonic and skin defect, leading to suitable closure of the fistula.
In plain wordsIn rats with a gut-to-skin fistula, BPC‑157 sped up healing of the gut and skin defects and closed the fistula.
- Peptide
- BPC-157
- Outcome
- IncreaseHealing of colonic and skin defect, fistula closure
- Study
ratn: not reported in source
Persistent colocutaneous fistula- Outcome group
- Wound healing · Gastrointestinal
- Studied dose
- 10 microg/kg, 10 ng/kg · drinking water (peroral) or intraperitoneal · until sacrifice at day 1, 3, 5, 7, 14, 21, or 28As given in this study (rat).
Source sentences
BPC 157 accelerated parenterally or perorally the healing of colonic and skin defect, leading to the suitable closure of the fistula
2 context sentences(design, population, supporting numbers)
We focused on the therapeutic effect of the stable gastric pentadecapeptide BPC 157 and how its action is related to nitric oxide (NO) in persistent colocutaneous fistula in rats (at 5 cm from anus, colon defect of 5 mm, skin defect of 5 mm); this peptide has been shown to be safe in clinical trials…
BPC 157 (10 microg/kg, 10 ng/kg) was applied i) in drinking water until the animals were sacrificed at post-operative day 1, 3, 5, 7, 14, 21, and 28; or ii) once daily intraperitoneally (first application 30 min following surgery, last 24 h before sacrifice) alone or with N(G)-nitro-L-arginine methy…